Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Flavonolignans for treatment of autoimmune inflammatory diseases

A flavonoid lignan, inflammatory disease technology, applied in metabolic diseases, skeletal diseases, drug combinations, etc., can solve problems such as the abnormal effect of silibinin lipid metabolism in the liver and other problems, and achieve the effect of reducing liver abnormality

Inactive Publication Date: 2018-10-23
MACAU UNIV OF SCI & TECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] To date, the effect of silibinin on lipid metabolism and liver abnormalities in patients with RA has never been studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flavonolignans for treatment of autoimmune inflammatory diseases
  • Flavonolignans for treatment of autoimmune inflammatory diseases
  • Flavonolignans for treatment of autoimmune inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0228] Induction of AIA

[0229] The AIA model was induced on day 0 by a single subcutaneous injection of 0.1 ml of a freshly prepared suspension containing 62.5 μg of Mycobacterium tuberculosis (MT) H37Ra (BD, Sparks, USA) into the tail of the animal. Rats in the control group were injected with an equal volume of normal saline instead of MT suspension. In the experiment lasting 42 days, AIA rats (n=10-12) were given 100, 200 mg / kg of silibinin (20% PEG400: 15% Cremophor EL: 5% ethanol: 60% saline solution) every day , or oral administration of 7.6 mg / kg MTX or blank solvent (20% PEG400: 15% Cremophor EL: 5% ethanol: 60% saline).

[0230] Assess the severity of arthritis and the effect of silibinin treatment

[0231] Disease severity and progression were assessed by measuring the volume and body weight of both hindpaws with a plethysmograph and a precision balance every two or three days after induction of arthritis. In order to accurately assess the arthritis score, each ...

Embodiment 2

[0302] MCD diet-induced mouse NASH model

[0303] Male wild-type C57Bl / 6 mice were fed with normal diet MCS (China Nutrition Animal Feed High-Tech Co., Ltd., China, #TP 3005GS) and MCD (China Nutrition Animal Feed High-Tech Co., Ltd., #TP3005G) for 8 weeks. Tables 15 and 16 give the compositions of the feeds, respectively. The animals were randomly divided into four groups (n=10): 1) the control group, fed with MCS feed; 2) fed with high-fat MCD feed; 3) fed with MCD feed and administered 150 mg / kg silibinin orally; 4) fed with MCD Feed and orally administered 300mg / kg silibinin. Silybin was dissolved in 35% PEG400: 15% Cremophor EL: 5% ethanol: 45% saline. Body weights were measured every two or three days during induction and during intervention.

[0304] At the end of the 8th week, the mice were sacrificed by ether anesthesia. The livers were immediately removed and weighed. Most of the livers were quickly frozen in liquid nitrogen, and the rest were fixed in 10% formal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome.Further provided is a method for reducing the risk of a cardiovascular disease in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism and a method for reducing hepatic abnormalities and reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by hepatic abnormalities. Still further provided is a methodfor reducing liver damages associated with the treatment of rheumatoid arthritis with a disease-modifying antirheumatic drug or a non-steroidal anti-inflammatory drug.

Description

technical field [0001] The invention relates to the application of flavonoid lignans in the preparation of drugs for reducing abnormal lipid metabolism and inflammation of subjects. The subject is a mammal, such as a human, and suffers from an autoimmune inflammatory disease, specifically autoimmune arthritis, preferably (but not limited to) rheumatoid arthritis, with abnormal lipid metabolism. Abnormalities in lipid metabolism may specifically be reduced HDL cholesterol levels, normal or slightly increased total cholesterol levels, normal or slightly increased LDL cholesterol levels, normal or slightly increased triglyceride levels, and optionally further With liver abnormalities. The flavonoid lignans of the present invention can be used in subjects suffering from liver disease, metabolic syndrome, obesity, diabetes or hypertension. Also provided is the application of flavonoid lignans in the preparation of a drug for reducing the risk of cardiovascular disease in a subjec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/357A61K31/352A61K31/7048A61P1/16A61P29/00A61P37/02A61P19/02A61P3/00A61P3/06
CPCA61P1/16A61P3/00A61P3/06A61P19/02A61P29/00A61P37/02A61K31/352A61K31/357A61K31/7048
Inventor 谢莹刘良周华
Owner MACAU UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com